Cargando…
Combined Effect of Bortezomib and Menadione Sodium Bisulfite on Proteasomes of Tumor Cells: The Dramatic Decrease of Bortezomib Toxicity in a Preclinical Trial
Tumor growth is associated with elevated proteasome expression and activity. This makes proteasomes a promising target for antitumor drugs. Current antitumor drugs such as bortezomib that inhibit proteasome activity have significant side effects. The purpose of the present study was to develop effec...
Autores principales: | Astakhova, Tatiana M., Morozov, Alexey V., Erokhov, Pavel A., Mikhailovskaya, Maria I., Akopov, Sergey B., Chupikova, Natalia I., Safarov, Ruslan R., Sharova, Natalia P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209890/ https://www.ncbi.nlm.nih.gov/pubmed/30257462 http://dx.doi.org/10.3390/cancers10100351 |
Ejemplares similares
-
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005) -
The ATP/Mg(2+) Balance Affects the Degradation of Short Fluorogenic Substrates by the 20S Proteasome
por: Morozov, Alexey, et al.
Publicado: (2022) -
Different characteristics between menadione and menadione sodium bisulfite as redox mediator in yeast cell suspension
por: Yamashoji, Shiro
Publicado: (2016) -
The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013) -
Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)